Anti-IL-23 therapy(Band Therapeutics, LLC)

NORTH CHICAGO, IL, USA I July 26, 2023 I AbbVie (NYSE: ABBV ) today announced the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of SKYRIZI ® (risankizumab) compared to Otezla ® (apremilast) among adult patients with moderate plaque psoriasis eligible for systemic therapy. 1 This study achieved all primary and ranked secondary endpoints with no new safety signals identified. 1 "This study highlights the efficacy of SKYRIZI compared to Otezla in helping systemic-eligible patients achieve high levels of skin clearance and reinforces the safety profile observed in previous studies," said Mudra Kapoor, M.D., vice president, global medical affairs, immunology, AbbVie. "These head-to-head data are crucial to help patients and their doctors make informed treatment decisions for uncontrolled disease and add to the body of evidence supporting SKYRIZI as a treatment option for adults living with moderate psoriasis." Highlights from this open-label, efficacy assessor-blinded study include: The safety profile for risankizumab in this study was consistent with previously reported studies; it was well-tolerated with no new safety signals identified. 1 The most frequent adverse events (reported in ≥5%) in risankizumab-treated patients were COVID-19, nasopharyngitis and upper respiratory tract infection. 1 Diarrhea, nausea and headache were most frequent among apremilast-treated patients. 1 Serious adverse events were reported in 0.8% and 2.9% of risankizumab-treated patients and 1.7% and 2.1% of apremilast-treated patients in Periods A and B, respectively. 1 During Period A and Period B among the re-randomization arms, 6.8% and 5.2% of apremilast-treated patients discontinued treatment due to an adverse event, respectively, while no patient discontinued on risankizumab; on the continuous risankizumab arm, one patient discontinued due to an adverse event. 1 "As a physician, it's crucial to validate different options that can achieve high treatment targets, and this study provides practice-relevant data," said lead study investigator, Linda Stein Gold, M.D., director of clinical research, department of dermatology, Henry Ford Health System. "These data reinforce the efficacy of SKYRIZI for use in systemic-eligible moderate psoriasis patients with an observed safety profile similar to prior studies." Based on analyses of the Treatment Satisfaction Questionnaire for Medication version 9 (TSQM-9), which were pre-specified unranked endpoints, risankizumab-treated patients reported greater treatment satisfaction at Week 16, with higher scores (out of 100) in all three domains of satisfaction with effectiveness (80.6), satisfaction with convenience (84.9) and global satisfaction (86.2) compared to apremilast-treated patients (46.9, 69.0 and 47.7, respectively; nominal p-value <0.001 for all comparisons). 1 SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally. About Psoriasis Psoriasis is a chronic, immune-mediated, inflammatory skin condition that produces thickened, scaling skin due to rapid growth of skin cells. 2 It affects around 2-3% of people worldwide. 3 People with psoriasis also experience a significant emotional, psychological and social burden that can negatively impact their quality of life. 4 About IMMpulse Study 1,5 IMMpulse is a Phase 4, global, multicenter, randomized, open-label, efficacy assessor-blinded, active comparator study examining the effect of risankizumab (150 mg X 1 s.c at wk0, wk4, wk16, wk28, wk40) compared to apremilast (30 mg BID oral following titration) in adults with moderate plaque psoriasis who are candidates for systemic therapy. Patients must have stable moderate psoriasis at both screening and baseline, defined as: 1) BSA ≥10% and ≤15%; 2) PASI ≥12; 3) sPGA =3 (moderate) to enter the study. The study design comprised a screening period of up to 35 days, a 52-week treatment period and a follow-up phone call for safety. The 52-week treatment duration included two periods: Period A from Weeks 0 to 16, which evaluated the superiority of risankizumab over apremilast, and Period B from Weeks 16 to 52, which evaluated the outcomes following re-randomization to risankizumab versus continuing apremilast in patients who were PASI 75 non-responders with apremilast at Week 16. About SKYRIZI ® (risankizumab) SKYRIZI is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. 6 IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases, including psoriasis. 6 EU Indications and Important Safety Information about SKYRIZI ® (risankizumab) 7 Indications Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. Important Safety Information Risankizumab is contraindicated in patients hypersensitive to the active substance or to any of the excipients, and in patients with clinically important active infections (e.g. active tuberculosis). Risankizumab may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated. Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves. Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Prior to initiating therapy with risankizumab, completion of all appropriate immunisations should be considered according to current immunisation guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment. If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated. The most frequently reported adverse reactions were upper respiratory infections (from 13% in psoriasis to 15.6% in Crohn's disease). Commonly (greater than or equal to 1/100 to less than 1/10) reported adverse reactions included tinea infections, headache, pruritus, rash, fatigue and injection site reactions. This is not a complete summary of all safety information. Please see the SmPC for complete prescribing information. Globally, prescribing information varies; refer to the individual country product label for complete information. About the British Journal of Dermatology (BJD) The British Journal of Dermatology (BJD) is a top-ranked international dermatology journal, publishing the highest-quality research to advance the understanding and management of skin disease to improve patient outcomes. The BJD is one of the journals of the British Association of Dermatologists, the professional membership body for dermatologists in the UK. Oxford University Press (OUP) is BAD's publishing partner. OUP publishes over 500 academic and research journals covering a broad range of subject areas, two-thirds of which are published in collaboration with learned societies and other international organizations. OUP has been publishing journals for more than a century and, as the world's largest university press, has more than 500 years of publishing expertise. For more information, visit academic.oup.com . About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on Twitter , Facebook , Instagram , YouTube and LinkedIn . References: SOURCE: AbbVie

A greater proportion of patients achieved 100 percent improvement in skin clearance at the highest dose level tested compared to placebo, at week 16 Phase 3 clinical development in moderate-to-severe plaque psoriasis is planned SPRING HOUSE, Pa., July 4, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from its Phase 2b FRONTIER 1 clinical trial evaluating the novel, first and only oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis (PsO).1 The trial achieved all primary and secondary efficacy endpoints. A greater proportion of patients who received JNJ-2113 achieved PASI 75 (primary endpoint) as well as PASI 90 and PASI 100 (75, 90 and 100 percent improvement in skin lesions as measured by the Psoriasis Area and Severity Index, respectively)a compared to placebo, at week 16.1 Trial results for JNJ-2113 demonstrated a profile1 that supports its advancement into Phase 3 clinical development for moderate-to-severe plaque PsO in adult patients. JNJ-2113 is a novel oral IL-23R antagonist peptide that binds with high affinity to the IL-23R and has properties that allow it to be absorbed with oral dosing.2,3 The IL-23/IL-23R signaling pathway plays a critical role in the pathogenesis of immune-mediated inflammatory diseases, including PsO.4,5 JNJ-2113 selectively and potently blocks IL-23 signaling and downstream inflammatory cytokine production.2,6 PASI 75 Results – Primary Endpoint The proportions of adult patients receiving JNJ-2113 (n=212)1 who achieved PASI 75 demonstrated the following dose responses at week 16 compared to 9.3 percent of patients receiving placebo (n=43) (nominal p ≤0.002 for all comparisons):1 37.2 percent at 25 mg daily (n=43) 51.2 percent at 25 mg twice daily (n=41) 58.1 percent at 50 mg daily (n=43) 65.1 percent at 100 mg daily (n=43) 78.6 percent at 100 mg twice daily (n=42) PASI 90 Results – Secondary Endpoint The proportions of adult patients receiving JNJ-2113 who achieved PASI 90 demonstrated the following dose responses at week 16 compared to 2.3 percent of patients receiving placebo (n=43) (nominal p ≤0.002 for all comparisons):1 25.6 percent at 25 mg daily (n=43) 26.8 percent at 25 mg twice daily (n=41) 51.2 percent at 50 mg daily (n=43) 46.5 percent at 100 mg daily (n=43) 59.5 percent at 100 mg twice daily (n=42) PASI 100 Results – Secondary Endpoint The proportions of adult patients receiving JNJ-2113 who achieved PASI 100 also demonstrated the following dose responses at week 16 compared to 0 percent of patients receiving placebo (n=43) (nominal p ≤0.05 for all comparisons):1 11.6 percent at 25 mg daily (n=43) 9.8 percent at 25 mg twice daily (n=41) 25.6 percent at 50 mg daily (n=43) 23.3 percent at 100 mg daily (n=43) 40.5 percent at 100 mg twice daily (n=42) Treatment was generally well tolerated, and the proportions of patients with adverse events were comparable between patient groups.1 The proportion of participants experiencing one or more adverse events (AEs) was 52.4 percent (n=111) in the combined JNJ-2113 group and 51.2 percent (n=22) in the placebo group.1 Although there was variability across the treatment groups, there was no evidence of a dose-dependent increase in the occurrence of specific AEs across the JNJ-2113 treatment groups.1 The most frequent system organ class involved in AEs in all groups was infections and infestations, which were 30.2 percent (n=64) vs. 27.9 percent (n=12) in the combined JNJ-2113 group vs. placebo group, respectively; of these, the most common were comparable between groups: COVID-19 (10.8 percent [n=23] vs. 11.6 percent [n=5]), nasopharyngitis (7.1 percent [n=15] vs. 4.7 percent [n=2]) and upper respiratory tract infection (2.4 percent [n=5] vs. 2.3 percent [n=1]).1 "Patients are looking for more flexible and convenient treatment options to manage the signs and symptoms of psoriasis, and these positive early results for JNJ-2113 are encouraging," said Robert Bissonnette, M.D., FRCPC, Chief Executive Officer and Medical Director, Innovaderm, Montreal, Canada, and Lead Investigator of the FRONTIER clinical trial.b "The majority of people living with moderate-to-severe plaque psoriasis are eligible for but are still not receiving advanced therapies.c,7 For many patients, a pill is preferable to an injection.d,8" "The development of a novel oral therapy that specifically targets IL-23R could potentially change the treatment paradigm for patients living with moderate-to-severe plaque psoriasis," said Lloyd Miller, M.D., Ph.D., Vice President, Immunodermatology Disease Area Stronghold Leader, Janssen Research & Development, LLC. "Until now, advanced psoriasis treatments have been largely limited to injectable biologics. An oral therapy that can uniquely inhibit the IL-23 pathway by directly targeting the IL-23 receptor could help address the needs and preferences of patients, and may offer greater freedom, with the aim of driving greater adoption of advanced treatment." These findings from the FRONTIER 1 clinical trial suggest the potential of JNJ-2113 across the spectrum of additional IL-23-mediated diseases, and as a next step, Janssen plans to advance JNJ-2113 into Phase 3 development for moderate-to-severe plaque PsO and initiate a Phase 2b clinical trial for adults living with ulcerative colitis. Editor's Notes: The PASI score grades the amount of surface area on each body region that is covered by PsO plaques and the severity of plaques for their redness, thickness and scaliness.9 Dr. Robert Bissonnette is a paid consultant for Janssen. He has not been compensated for any media work. This survey included a total of 414 respondents from Germany, Japan, Spain, the UK and the U.S.7 This survey included a total of 395 respondents from the U.S., Europe and Japan.8 About FRONTIER 1 (NCT05223868) The FRONTIER 1 Phase 2b trial (NCT05223868) is a randomized, multicenter, double-blind, placebo-controlled clinical trial that evaluated three once-daily dosages and two twice-daily dosages of JNJ-2113 taken orally.1,10 It was designed to assess the efficacy and safety of JNJ-2113 in patients with moderate-to-severe plaque PsO.1 255 participants were randomized into six treatment groups (placebo [n=43], 25 mg daily [n=43], 25 mg twice daily [n=41], 50 mg daily [n=43], 100 mg daily [n=43], 100 mg twice daily [n=42]).1 The total duration of the trial was up to 24 weeks, which included a screening period of less than or equal to four weeks, a 16-week treatment period and a four-week safety follow-up period.1 The primary endpoint of the clinical trial was the proportion of patients achieving PASI 75 at 16 weeks.1 Secondary endpoints include change from baseline in PASI total score at week 16, percentage of participants achieving PASI 90 and PASI 100 score at week 16, percentage of participants achieving an Investigator's Global Assessment (IGA) score of cleared (0) or minimal (1) at week 16, change from baseline in body surface area (BSA) at week 16, change from baseline in Psoriasis Symptoms and Signs Diary (PSSD) symptoms scores at week 16, percentage of participants achieving PSSD symptoms score=0 at week 16 in participants with a baseline symptoms score >=1, percentage of participants achieving a Dermatology Life Quality Index (DLQI) of 0 or 1 at week 16 in participants with baseline DLQI Score >1, change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS-29) domain score at week 16, percentage of participants who achieve >= 5-point improvement from baseline in PROMIS-29 domain score at week 16, and number of participants with adverse events and serious adverse events up to 24 weeks.10 About Plaque Psoriasis (PsO) Plaque PsO is an immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful.11 It is estimated that eight million Americans and more than 125 million people worldwide live with the disease.12 Nearly one-quarter of all people with plaque PsO have cases that are considered moderate to severe.12 Living with plaque PsO can be a challenge and impact life beyond a person's physical health, including emotional health, relationships, and handling the stressors of life.13 About JNJ-2113 JNJ-2113 (formerly PN-235) was discovered and is being developed pursuant to the license and collaboration agreement between Protagonist Therapeutics and Janssen Biotech, Inc. Janssen retains exclusive worldwide rights to develop JNJ-2113 in Phase 2 clinical trials and beyond, and to commercialize compounds derived from the research conducted pursuant to the agreement against a broad range of indications.14 JNJ-2113 is an oral IL-23R antagonist peptide that binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in human T cells.6 The license and collaboration agreement established between Protagonist and Janssen Biotech, Inc. in 2017 enabled the companies to work together to discover and develop next-generation compounds that ultimately led to JNJ-2113.15,16 About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Learn more at . Follow us at and . Janssen Research & Development, LLC; Janssen Biotech, Inc.; and Janssen Scientific Affairs, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding JNJ-2113. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at , or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. References 1 Bissonnette R, Pinter A, Ferris L, et al. Data Presentation. A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER 1. Presented at WCD 2023, July 3-8. 2 Fourie A, et al. First-In-Class Oral Peptide Systemically Targeting the Il-23 Pathway. Presented at ISID 2023, May 10-13. Available at: (JNJ77242113%20Concurrent)_final.pdf. Accessed June 2023. 3 Dougherty PG, et al. Understanding Cell Penetration of Cyclic Peptides. Chem Rev. 2019 Sep 11; 119(17): 10241–10287. 4 Razawy W, et al. The role of IL–23 receptor signaling in inflammation–mediated erosive autoimmune arthritis and bone remodeling. Eur J Immunol. 2018 Feb; 48(2): 220–229. 5 Tang C, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012 Feb; 135(2): 112–124. 6 Protagonist Therapeutics. Press Release. Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113. Available at: . Accessed June 2023. 7 Data on File. Janssen. Decision Resources & Internal Claims Research. Truven Health Analytics Data. 8 Data on File. Janssen. Patient Preference Survey: Oral vs. Injectable. 9 Thompson Jr, D. How the Psoriasis Area and Severity Index Works. Everyday Health. Available at: . Accessed June 2023. 10 Clinicaltrials.gov. A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis (FRONTIER 1). Identifier NCT05223868. . Accessed June 2023. 11 National Psoriasis Foundation. About Psoriasis. Available at: . Accessed June 2023. 12 National Psoriasis Foundation. Psoriasis Statistics. Available at: . Accessed June 2023. 13 National Psoriasis Foundation. Life with Psoriasis. Available at: . Accessed June 2023. 14 Protagonist Therapeutics. Press Release. Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists. Available at: . Accessed June 2023. 15 Protagonist Therapeutics. Press Release. Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis. Available at: . Accessed June 2023. 16 Johnson & Johnson. Press Release. Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. For The Oral Interlukin-23 Receptor Antagonist Drug Candidate For The Treatment of Inflammatory Bowel Disease. Available at: . Accessed June 2023. Media Contact: Bridget Kimmel Mobile: (215) 688-6033 Investor Contact: Raychel Kruper Office: (732) 524-6164 SOURCE Janssen Pharmaceutical Companies of Johnson & Johnson